Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations

References

• BerrySJCoffeyDSWalshPCEwingLLThe development of human benign prostatic hyperplasia with ageJ Urol198413234744796206240
   PubMed Web of Science ®Google Scholar
• BraunMWassmerGKlotzTReifenrathBMathersMEngelmannUEpidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’Int J Impot Res200012630531111416833
   PubMed Web of Science ®Google Scholar
• FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging StudyJ Urol1994151154618254833
   PubMed Web of Science ®Google Scholar
• LiMKGarciaLARosenRLower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countriesBJU Int20059691339135416287456
   PubMed Web of Science ®Google Scholar
• RosenRAltweinJBoylePLower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)Eur Urol200344663764914644114
   PubMed Web of Science ®Google Scholar
• LaumannEOPaikARosenRCSexual dysfunction in the United States: prevalence and predictorsJAMA1999281653754410022110
   PubMed Web of Science ®Google Scholar
• BlankerMHBohnenAMGroeneveldFPCorrelates for erectile and ejaculatory dysfunction in older Dutch men: a community-based studyJ Am Geriatr Soc200149443644211347788
   PubMed Web of Science ®Google Scholar
• WeiJTCalhounEJacobsenSJUrologic diseases in America project: benign prostatic hyperplasiaJ Urol200517341256126115758764
   PubMed Web of Science ®Google Scholar
• GacciMCoronaGSalviMA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol2012615994100322405510
   PubMed Web of Science ®Google Scholar
• AnderssonKEde GroatWCMcVaryKTTadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionNeurourol Urodyn201130329230121284024
   PubMed Web of Science ®Google Scholar
• FibbiBMorelliAVignozziLCharacterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tractJ Sex Med201071 Pt 1596919796053
   PubMed Web of Science ®Google Scholar
• CurranMPTadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunctionDrugs Aging201229977178123018613
   PubMed Web of Science ®Google Scholar
• WrightPJComparison of phosphodiesterase type 5 (PDE5) inhibitorsInt J Clin Pract200660896797516780568
   PubMed Web of Science ®Google Scholar
• KütheAWiedenrothAMägertHJExpression of different phosphodiesterase genes in human cavernous smooth muscleJ Urol2001165128028311125425
   PubMed Web of Science ®Google Scholar
• UckertSKuczykMACyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tractHandb Exp Pharmacol201120220252754221290241
   PubMedGoogle Scholar
• UckertSStiefCGMayerMJonasUHedlundPDistribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tractWorld J Urol200523636837316331503
   PubMed Web of Science ®Google Scholar
• FüllhaseCHennenbergMGieseAPresence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivityJ Urol201319041430143523545097
   PubMed Web of Science ®Google Scholar
• ZhaoCKimSHLeeSWActivity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasiaBJU Int2011107121943194721054754
   PubMed Web of Science ®Google Scholar
• UckertSHedlundPWaldkirchEInteractions between cGMP-and cAMP-pathways are involved in the regulation of penile smooth muscle toneWorld J Urol200422426126615045518
   PubMed Web of Science ®Google Scholar
• UckertSSormesMKediaGEffects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissueUrology200871352653018342202
   PubMed Web of Science ®Google Scholar
• OgerSBehr-RousselDGornyDCombination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitroEur Urol201057469970719428174
   PubMed Web of Science ®Google Scholar
• TinelHStelte-LudwigBHütterJSandnerPPre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptomsBJU Int20069861259126316956354
   PubMed Web of Science ®Google Scholar
• UckertSKütheAJonasUStiefCGCharacterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostateJ Urol200116662484249011696815
   PubMed Web of Science ®Google Scholar
• DongYHaoLShiZWangGZhangZHanCEfficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysisUrol Int2013911101823816815
   PubMed Web of Science ®Google Scholar
• PorstHRoehrbornCGSecrestRJEslerAViktrupLEffects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studiesJ Sex Med20131082044205223782459
   PubMed Web of Science ®Google Scholar
• DmochowskiRRoehrbornCKliseSXuLKaminetskyJKrausSUrodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trialJ Urol201018331092109720092847
   PubMed Web of Science ®Google Scholar
• KlonerRAJacksonGEmmickJTInteraction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive menJ Urol20041725 Pt 11935194015540759
   PubMed Web of Science ®Google Scholar
• GiulianoFKaplanSACabanisMJAstrucBHemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjectsUrology20066761199120416765179
   PubMed Web of Science ®Google Scholar
• KaplanSAGonzalezRRTeAECombination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunctionEur Urol20075161717172317258855
   PubMed Web of Science ®Google Scholar
• BecharaARomanoSCasabéAComparative efficacy assessment of tamsulosin vs tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot studyJ Sex Med2008592170217818638006
   PubMed Web of Science ®Google Scholar
• SinghDVMeteUKMandalAKSinghSKA comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasiaJ Sex Med201411118719624165272
   PubMed Web of Science ®Google Scholar
• LiguoriGTrombettaCDe GiorgiGEfficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary reportJ Sex Med20096254455219138360
   PubMed Web of Science ®Google Scholar
• ChungBHLeeJYLeeSHYooSJLeeSWOhCYSafety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTSInt J Impot Res200921212212819194451
   PubMed Web of Science ®Google Scholar
• CasabéARoehrbornCGDa PozzoLFEfficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasiaJ Urol2014191372773324096118
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMcVaryKTElion-MboussaAViktrupLTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding studyJ Urol200818041228123418722631
   PubMed Web of Science ®Google Scholar
• DonatucciCFBrockGBGoldfischerERTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyBJU Int201110771110111621244606
   PubMed Web of Science ®Google Scholar
• ForgueSTPhillipsDLBeddingAWEffects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsBr J Clin Pharmacol2007631243516869816
   PubMed Web of Science ®Google Scholar
• RingBJPattersonBEMitchellMIEffect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivoClin Pharmacol Ther2005771637515637532
   PubMed Web of Science ®Google Scholar
• WeeksJLZoraghiRBeasleyASekharKRFrancisSHCorbinJDHigh biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patientsInt J Impot Res20051715915538396
   PubMed Web of Science ®Google Scholar
• KlonerRAHutterAMEmmickJTMitchellMIDenneJJacksonGTime course of the interaction between tadalafil and nitratesJ Am Coll Cardiol200342101855186014642699
   PubMed Web of Science ®Google Scholar
• GoldfischerEKowalczykJJClarkWRHemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trialUrology201279487588222341603
   PubMed Web of Science ®Google Scholar